Infliximab for the treatment of rheumatoid arthritis-Reference-Cited by-同舟云学术

Infliximab for the treatment of rheumatoid arthritis

Published:2002-07-22 Issue:7 Volume:2010 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Blumenauer Barbara BTB¹,Judd Maria²,Wells George A³,Burls Amanda⁴,Cranney Ann⁵,Hochberg Marc C⁶,Tugwell Peter⁷,Lopez-Olivo Maria Angeles⁸

Affiliation:

1. 206-300 Columbia St Kamloops British Columbia Canada V2C 6L1

2. Canadian Health Services Research Foundation/Fondation canadienne de la recherche sur les services de santé; Research Use/Agente principale de programme, Utilisation de la Recherche; 1565 avenue Carling Avenue Suite/pièce 700 Ottawa Ontario Canada K1Z 8R1

3. University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7

4. University of Oxford; Department of Primary Health Care; Rosemary Rue Building Headington Oxford Birmingham UK OX3 7LF

5. Ottawa Hospital; Division of Rheumatology; 1053 Carling Ave Ottawa Ontario Canada K1Y 4E9

6. University of Maryland; School of Medicine; 10 S Pine St MSTF 8-34 Baltimore MD USA 21201

7. Ottawa Hospital; Centre for Global Health, Institute of Population Health, Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5

8. The University of Texas, M.D. Anderson Cancer Center; General Internal Medicine, Ambulatory Treatment and Emergency Care; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003785/fullpdf

Reference21 articles.

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis;Lipsky;The New England Journal of Medicine,2000

2. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrextae in rheumatoid arthritis;Maini;Arthritis and Rheumatism,1998

3. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial;Maini;Lancet,1999

4. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy;Brennan;British Journal of Rheumatology,1997

5. Treatment of rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor alpha;Elliott;Arthritis and Rheumatism,1993

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances in rheumatoid arthritis;BMJ;2024-01-17

2. Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates;Journal of Clinical Medicine;2022-10-11

3. The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan;International Journal of Clinical Practice;2022-08-26

4. Nucleic Acids for Potential Treatment of Rheumatoid Arthritis;ACS Applied Bio Materials;2022-02-04

5. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study;Frontiers in Medicine;2020-08-06